Monte Rosa Therapeutics (GLUE)

• Market cap: $1.65B
• 1 day: 8.72%
• 5 days: 61.01%
• 1 month: 41.79%
• 3 months: 228.27%
• 6 months: 400.2%
• Year to date: 65.32%
• 1 year: 322.54%
• 5 years: 19.5%
• 10 years: 19.5%
• Sector: Healthcare
• Industry: Biotechnology

About: Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Employees: 147